Hurvitz SA, Park YH, Bardia A, Quiroga V, Lopez-Valverde V, Steinseifer J, Moore HM, Spera G, Xue C, Fasching P (2021)
Publication Type: Conference contribution
Publication year: 2021
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S1285-S1286
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2021.08.2086
APA:
Hurvitz, S.A., Park, Y.H., Bardia, A., Quiroga, V., Lopez-Valverde, V., Steinseifer, J.,... Fasching, P. (2021). Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study. In ANNALS OF ONCOLOGY (pp. S1285-S1286). AMSTERDAM: ELSEVIER.
MLA:
Hurvitz, S. A., et al. "Neoadjuvant giredestrant (GDC-9545) + palbociclib (palbo) vs anastrozole (A) plus palbo in post-menopausal women with oestrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+/HER2-eBC): Interim analysis of the randomised, open-label, phase II coopERA BC study." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2021. S1285-S1286.
BibTeX: Download